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ACKGROUND: The prevalence of 
metabolic syndrome (MetS) in USA 
and Makassar are  22% and  23.7%. The 
prevalence of Non Alcoholic Steatosis Hepatosis 
(NASH) in MetS has not been reported. Study 
in Non-alcoholic Fatty Liver Disease (NAFLD) 
is 25–90 % in obesity patients. In NASH, there is 
accumulation of lipid in hepatocyte (raised free 
fatty acid level), raised stress oxidative (decreased 
total antioxidant status), raised of inﬂammation 
process (decreased adiponectin) and hepatic 
ﬁbrotic process (raised TGF 1). The aim of this 
study is to investigate the correlation of free fatty 
acid, total antioxidant status, adiponectin and 
TGF- 1 with the occurrence of  NASH.
METHODS: This was a case control study in 
man aged ≥ 30 years old. Metabolic syndrome 
(MetS) was deﬁned by IDF categories. NASH was 
deﬁned as fatty liver plus raised type IV collagen 
level ≥ 140 ng/ml and Alanine Transferase (ALT) 
level 1.5 X upper normal limit. 
RESULT: The samples consisted of 8 MetS 
subjects, 11 MetS subjects with fatty liver and 2 
MetS subjects with suspect NASH. Low level of 
adiponectin and high level free fatty acid led to 
progression from Fatty Liver (FL) to NASH. Level 
of total antioxidant and Level of TGF- 1 were 
relatively steady in NASH.
CONCLUSION: The level of Free Fatty acid in 
subjects with MetS-FL was higher than in subjects 
with MetS, but was lower than in subjects with 
MetS-NASH. No difference in total antioxidants 
status level was observed among all groups. Level 
of adiponectin decreased in subjects with MetS-FL and 
MetS-NASH compared with subjects with MetS only. The 
level of TGF- 1 increased in subjects with MetS-FL more 
than in subjects with MetS only, and was steady low in 
subjects with MetS-NASH.
KEYWORDS: Metabolic Syndrome, NASH, Free Fatty 
Acid, Total Antioxidant Status, Adiponectin , Transforming 
Growth Factor 1.
The prevalence of metabolic syndrome in USA and in 
Makassar are 22% and 23,7% respectively. Individuals with 
metabolic syndrome seemingly are susceptible to other 
conditions such as Polycystic Ovary Syndrome (PCOS), 
fatty liver, asthma, sleep disorders and some form of 
cancers (1).
Nonalcoholic steatosis hepatitis (NASH) is deﬁned by 
the presence of hepatomegaly, increase of aminotransferase 
serum and lacked history of signiﬁcant alcohol intake 
but in whom liver histology resembled that of alcoholic 
liver disease (2). NASH—the most severe form of non-
alcoholic fatty liver disease (NAFLD)—is emerging as a 
common clinically important type of chronic liver disease 
industrialized countries. Most cases of NASH occur in 
patient with obesity (25–95%), type 2 diabetes mellitus 
(21–55%) and hyperlipidemia (23–92%). There was no data 
of occurrence of NASH in metabolic syndrome (3).
Insulin resistance and increased free fatty acid level 
were major features in pathomechanism of NASH. Insulin 
resistance and hyperlipidemia caused lipid accumulation 
such as triglyceride, hepatocytes that were more supceptible 
to oxidative sress, cytokines expression, inﬂammation, and 
decrease in ATP triggering hepatocyte injury (4).
Inﬂammation, a combined process of stress oxidative 
effect, lipid peroxidation and abnormally cytokine 
expression especially TNF- , mediated the occurrence of 
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intrahepatic i nﬂammation, apoptosis, necrosis and 
ﬁbrosis of hepatocytes.  It also increased the production 
of TGF- 1, which could activate the steallate cells and 
caused c ell death (4). The liver normally r esponds 
to t he c hronic presence of oxidant pathway, s uch as 
those based on reduced g lutathione (GSH) and total 
antioxidant (5)
This study investigated the biochemical markers 
of F ree Fatty A cid ( FFA), Total A ntioxidant S tatus 
(TAOS), A diponectin, Transforming Growth Factor 
1 (TGF- 1), in the occurrence of NASH.
This study w as a n observational c ase control study. 
Metabolic s yndrome (MetS) was deﬁned b y IDF 
categories as waist circumference plus any two of the 
following factors: raised triglyceride level > 140 mg/
dl, reduced H DL c holesterol < 40 m g/dl ( in m an), 
raised blood pressure (systolic > 130 or diastolic > 85 
mmHg), raised fasting plasma glucose >  100 mg/dl. 
NASH was deﬁned as fatty liver plus raised type IV 
collagen level > 140 mg/dl and ALT level 1.5x upper 
normal limit.
Subjects c onsisted of 8  M ets subjects, 1 1 MetS 
subjects w ith f atty liver and 2  M etS subjects w ith 
suspect NASH. Informed c oncent from all subjects 
were obtained before subjects w ere enrolled in t his 
study.
Patients and Methods
Assay of Biochemical Markers
Serum were separated from fasting whole blood after 
centrifugation, and i mmediately kept a t -20ºC until 
measurement. Biochemical markers measured w ere 
free fatty a cid ( Roche,cat.No. 11383175001), TGF- 1 
(R&D, Cat.No. DB100), Total antioxidants status (Cat.
No. NX2332), Adiponectin ( Daichii C at.No. 376405 
lot 006RED), and c ollagen t ype I V (Daiichi, C at N o. 
348259 Lot No.CH01401).
Statistical Analysis
SPSS for windows ver 11.5 was used for all statistical 
and g raphical analysis. G eneral description of data 
were analyzed w ith univariate analysis t o mention 
minimum and maximum value, average, and standard 
deviation. T -test w as u sed to c ompare all factors 
between s ubjects w ith M etS-NASH and s ubjects 
without MetS-NASH. Bivariat and partial correlation 
analysis was used to analyze correlation of all factors. 
Results were considered signiﬁcant if P < 0,05.
1. FREE FATTY ACID
In s ubjects w ith M etS progressing into Fatty liver, 
there was a signiﬁcant increase in FFA level, while in 
the subjects w ith M etS progression into N ASH, t he 
level of FFA tended to decrease, as shown in Figure 1.
Results
Figure1. Means of free fatty acid level in Mets,
Mets With Fatty Liver and Mets with NASH 
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3. ADIPONECTIN
Figure 3 showed that the subjects with MetS-FL 
or MetS-NASH had lower level of Adiponectin 
compared to subjects with MetS only.
Figure 3. Means of free adiponectin in Mets, 
Mets With Fatty Liver and Mets with NASH 
4. TRANSFORMING GROWTH FACTOR -1  (TGF- 1)
In subjects with MetS progressing into fatty liver MetS, 
there was a signiﬁcant increased level of TGF-beta1, 
however in subjects with MetS-NASH it tended to 
decrease, as seen in ﬁgure 4. This might be due to the 
role of TGF-beta1 that only took place in the early stage 
of MetS to Fatty liver MetS. In the stage of MetS-NASH, 
this role might be displaced by other markers or collagen 
tissue might have already formed and thus lesser TGF-
beta1 could be detected.
Figure 4. Means of TGF-ß1 level in Mets, 
Mets With Fatty Liver and Mets with NASH 
 
Histopathologically, NASH is a part of a wide spectrum 
of Nonalcoholic fatty liver disease which found as a 
simple steatosis up to ﬁbrous steatosis (Ludwig, 2000)
We deﬁned NASH with combined measurement of USG, 
SGOT, and Collagen type IV. Resulted conditions (Mets, 
Fatty liver MetS, MetS suspect NASH) were probably 
due to a process that started from NAFLD up to NASH, 
and these were proved when we diagnosed the type of 
NASH by using liver biopsy with steatosis spectrum, 
steatohepatitis, and NASH.
There are several parameters that play roles in 
NASH pathomechanism, such as FFA, total antioxidant 
status, adiponectin and TGF-beta1.
The level of FFA decreased in MetS-NASH and this 
 ecnis deneppah taht ytivissergorp ralullec ot eud eb thgim
fatty liver MetS until NASH MetS and therefore FFA was 
Discussions
2. TOTAL ANTIOXIDANT STATUS
In this study, we found no signiﬁcant difference 
in the level of total antioxidant status in subjects 
with MetS and in subjects with MetS-Fatty liver, as 
can be seen in Figure 2. This might be due to the 
measured antioxidant was not an active antioxidant 
that played role in the pathobiology of NASH or 
 ,HSAN ni devlovni tnadixoitna eht esuaceb rehtie
worked simultaneously and thus did not show any 
signiﬁcant level difference.
Figure . Means of free total antio idant status level in Mets, 
Mets With Fatty Liver and Mets with NASH 
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Figure 5. Means of triglyceride level in Mets, 
Mets With Fatty Liver and Mets with NASH 
Reactive oxygen s pecies causes a  decrease in 
antioxidant enzymes, the measurement of antioxidant 
status represents the oxidative status in subjects with 
MetS along with Fatty Liver.
oxidized ( peroximal beta oxidation or m icrosomal 
W oxidation or it was esteriﬁed into triglyceride, see 
ﬁgure 5 ). The c hanges i n FFA concentration in t hese 
three conditions were further observed with a larger 
number of samples.
However, to prove this hypothesis, further research 
using larger s ample number and a lso a  c omparison 
using other antioxidants such as superoxide dismutase 
(SOD) is still needed. The evaluation of stress oxidative 
condition can also be done using thioredoxin.
Obesity and M etS will r esult in a n increased o f 
reactive oxygen species and altered lipid peroxidation 
and therefore result in inﬂammation that triggers the 
release of cytokines such as TNF-alfa and TGF-beta1, 
and a decreased in adiponectin level.
From the study of Yoon et al, hypoadiponectinemy 
occurred i n NAFLD s ubjects. I n animal study, 
adiponectin w as p rotective towards the alcoholic 
effect as well as nonalcoholic fatty liver disease. The 
recent study, has reported that hypoadiponectinemy 
was a picture of NASH that was non insulin resistance 
dependent and t hat t he decreased adiponectin l evel 
correlated t o the number o f necroinﬂammation 
and c ontributed t o the progression of t he s hape o f 
necroinﬂammation in NAFLD (Yoon, 2005).
Obesity also causes an increase of reactive oxygen 
species and a ltered lipid p eroxidation and t hus 
triggering inﬂammation which is marked by the release 
of c ytokines s uch as T NF-alfa and T GF-beta1 and a  
decrease of adiponectin. The continuous induction of 
TGF-beta1 will result in the formation of ﬁbrous and it 
is marked by the increased level of collagen type IV.
The f ull pathomechanism o f interaction of F FA, 
adiponectin, total antioxidant status,  TGF-beta1 and 
collagen type IV can be seen in ﬁgure 6.
Figure 6. From Fat to liver injury (Adapted from Jansen, 2004).
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Free fatty acid are taken up in the hepatocytes 
where they are either metabolized via peroxisomal and 
mithochondrial -oksidation or stored as triglycerides. 
VLDL is the rate –determining step in triglyceride 
export from the liver. In NASH its synthesis is 
decreased. The insulin-resistant state favours lipolysis 
in the adipose tissues, FFA synthesis and lipogenesis 
in the liver. The net result is hepatic fat inﬂammation. 
Continuous and superﬂuous FFA oxidation causes 
the generation of ROS in excess with oxidant stress 
as a result. Cytokines are produced in hepatocytes 
as well as in Kupffer cells. TGF-  stimulates hepatic 
stellate cells to produce collagen and cause liver 
ﬁbrosis, in addition these cells transform into 
myoﬁbroblasts with more collagen formation and an 
incresase of intrahepatic vascular resistance and portal 
hypertension. Chemokines attract monocytes and 
neutrophils with inﬂammation, more oxidant stress, 
hepatocellular apoptosis and injury as a result
The level of Free Fatty Acid in subjects wit MetS-FL 
was higher than in subjects with MetS, but was lower 
than in subjects with MetS-NASH. No difference in 
total antioxidant status level was observed among 
all groups. Level of adiponectin decreased in subjects 
with MetS-FL and MetS-NASH compared to subjects 
with Mets only. Level of TGF- 1 increased in subjects 
with MetS-FL more than in subjects with MetS only, 
and was steady to low in subjects with MetS-NASH.
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